文献速递结核与非结核分枝杆菌

评估快速结核药敏试验准确性的研究指南

Guidance for Studies Evaluating the Accuracy of Rapid Tuberculosis Drug-Susceptibility Tests.
PubMed 文献 · J Infect Dis · 2019-01-01

本文总结了快速分子诊断用于结核病药敏试验的分析性与临床研究设计要点,强调需评估结核及耐药检测性能与平台操作特征,以支持世界卫生组织评审和潜在政策推荐。

要点

  • 性能评估应包括分析性研究确认检测限及对全球代表性菌株耐药突变的检出能力。
  • 分析性评估后需多中心临床研究确认在预期使用地点和人群中的诊断性能。
  • 研究设计需同时评估检测性能和平台操作特征以支持政策推荐。

核心结论

  • 快速分子药敏试验的分析性与临床研究设计应系统评估检测性能和操作特征,以快速积累世界卫生组织评审所需证据。

研究设计与样本

  • 本文为方法学指南,总结分析性与临床研究的设计考虑,未报告具体样本量。

关键数值与推荐

  • 分析性研究应确认检测限和检测全球代表性菌株耐药突变的能力。
  • 分析性评估后应开展多中心临床研究确认在预期使用地点和人群中的诊断性能。

临床怎么用

  • 开展快速结核药敏试验评估时,应按分析性研究到多中心临床研究的顺序设计以支持政策转化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The development and implementation of rapid molecular diagnostics for tuberculosis (TB) drug-susceptibility testing is critical to inform treatment of patients and to prevent the emergence and spread of resistance. Optimal trial planning for existing tests and those in development will be critical to rapidly gather the evidence necessary to inform World Health Organization review and to support potential policy recommendations. The evidence necessary includes an assessment of the performance for TB and resistance detection as well as an assessment of the operational characteristics of these platforms. The performance assessment should include analytical studies to confirm the limit of detection and assay ability to detect mutations conferring resistance across globally representative strains. The analytical evaluation is typically followed by multisite clinical evaluation studies to confirm diagnostic performance in sites and populations of intended use. This paper summarizes the considerations for the design of these analytical and clinical studies.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Georghiou SB, Schumacher SG, Rodwell TC, et al. Guidance for Studies Evaluating the Accuracy of Rapid Tuberculosis Drug-Susceptibility Tests. J Infect Dis. 2019. PMID: 31593599. doi:10.1093/infdis/jiz106

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。